AXSM Axsome Therapeutics Inc.

3.25
0  0%
Previous Close 3.25
Open 3.3
Price To Book 12.04
Market Cap 85321802
Shares 26,252,862
Volume 139,722
Short Ratio 10.85
Av. Daily Volume 129,337

SEC filingsSee all SEC filings

  1. S-8 - Securities to be offered to employees in employee benefit plans 181013421
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181001471
  3. 8-K - Current report 181001354
  4. 8-K - Current report 18999762
  5. 8-K - Current report 18881572

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due 1Q 2019.
AXS-05
Smoking cessation
Phase 2/3 initiation announced July 17, 2017. Interim analysis due 4Q 2018. Interim efficacy analysis due 2019 with top-line data due 2H 2019 – 1H 2020.
AXS-05 ADVANCE-1
Agitation in patients with Alzheimer’s disease (AD)
Phase 3 interim efficacy analysis January 9, 2017 recommended trial to discontinue due to futility.
AXS-02 CREATE-1
Complex regional pain syndrome (CRPS)
Phase 3 initiated March 2016. Interim analysis April 26, 2018 recommended trial to continue. Interim efficacy analysis due 2H 2018.
AXS-05 STRIDE-1
Treatment resistant depression
Phase 3 interim efficacy analysis January 9, 2017 recommended trial continue to full enrollment.
AXS-02 COAST-1
Knee Osteoarthritis Associated with Bone Marrow Lesions
Phase 3 initiation contingent upon resources.
AXS-02
Chronic Low Back Pain Associated with Modic Changes
Phase 3 trial planned for 2018 with data due in 2019.
AXS-07
Migraine
Phase 2 data due 4Q 2018.
AXS-05 ASCEND
Major Depressive Disorder

SEC Filings

  1. S-8 - Securities to be offered to employees in employee benefit plans 181013421
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181001471
  3. 8-K - Current report 181001354
  4. 8-K - Current report 18999762
  5. 8-K - Current report 18881572
  6. 8-K - Current report 18880064
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 18815404
  8. 8-K - Current report 18812920
  9. DEF 14A - Other definitive proxy statements 18785989
  10. 8-K - Current report 18776106